Hormone receptor positive HER2 negative breast cancer

37 trials 20 recruiting MedDRA PT
37 Registered trials
20 Recruiting
25 Unique sponsors
26 Unique IMPs
27 Commercial trials
Drug classes (ATC)
— ATC code not specified 22
N Neurology/Psychiatry (ATC N) 1
L Oncology (ATC L) 13
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 15 substances
CDK inhibitor 3 substances
Antibody-drug conjugate (ADC) 2 substances
SERD 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Corticosteroid 1 substance
mTOR inhibitor 1 substance
PARP inhibitor 1 substance
Phase III: 15 Phase II: 7 Phase I/II: 3 Phase IV: 2 Phase I: 6 Phase I (Other): 2 Phase I (First in Human): 2

Filter these 37 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 37 trials

Phase III

15 trials
  • Celcuity Inc. Commercial
    ALPELISIB; DEXAMETHASONE; FULVESTRANT; GEDATOLISIB; PALBOCICLIB
    2022-502145-10-00 12 countries 2023 n=233
    Ended
  • Dualitybio Inc. Commercial
    DB-1303
    2023-507333-17-00 7 countries 2024 n=77
    Ended
  • Genentech Inc. Commercial
    EVEROLIMUS; EXEMESTANE; FULVESTRANT; GIREDESTRANT; TAMOXIFEN CITRATE
    2023-506821-12-00 4 countries 2023 n=59
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    NIRAPARIB TOSILATE MONOHYDRATE
    2023-504454-35-00 4 countries 2021 n=143
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-506921-12-00 8 countries 2018 n=424
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN
    2025-520582-51-00 7 countries 2025 n=211
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-503001-38-01 2 countries 2025 n=172
    Ended
  • Pfizer Inc. Commercial
    2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    2025-520566-22-00 14 countries 2025 n=153
    Recruiting
  • Relay Therapeutics Inc. Commercial
    CAPIVASERTIB; FULVESTRANT; RLY-2608
    2025-523083-21-00 14 countries 2025 n=272
    Recruiting
  • Stemline Therapeutics Inc. Commercial
    IMP not specified
    2024-515445-42-00 15 countries 2025 n=1,972
    Recruiting
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    RIBOCICLIB
    2024-515769-32-00 1 country 2019 n=1,684
    Ended
  • BOOG Study Center B.V. Academic
    ABEMACICLIB; PALBOCICLIB; RIBOCICLIB
    2024-516204-42-00 1 country 2017 n=1,050
    Ended
  • European Organisation For Research And Treatment Of Cancer Academic
    IMP not specified
    2022-501453-36-00 11 countries 2024 n=215
    Recruiting
  • Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi Academic
    IMP not specified
    2024-513442-10-00 5 countries n=252
    Not authorised
  • WSG Westdeutsche Studiengruppe GmbH Academic
    CAPIVASERTIB
    2024-511392-15-00 3 countries 2025 n=250
    Recruiting

Phase II

7 trials
  • Bicycletx Limited Commercial
    ZELENECTIDE PEVEDOTIN
    2024-517868-33-00 4 countries 2025 n=30
    Ended
  • Medica Scientia Innovation Research S.L. Commercial
    IMP not specified
    2023-509591-42-00 3 countries 2021 n=162
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN; PEMBROLIZUMAB
    2024-514376-40-00 1 country 2025 n=10
    Recruiting
  • BOOG Study Center B.V. Academic
    ALPELISIB; ALPELISIB, ALPELISIB
    2024-514965-20-00 1 country 2022 n=130
    Ended
  • Istituto Europeo Di Oncologia S.r.l. Academic
    FLUOROESTRADIOL F-18
    2024-519792-25-00 1 country 2026 n=26
    Recruiting
  • Unicancer Academic
    2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE; FULVESTRANT
    2025-521982-29-00 1 country n=51
    Pending
  • Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group Academic
    ELACESTRANT; RIBOCICLIB
    2023-505758-17-00 2 countries 2025 n=120
    Recruiting

Phase I/II

3 trials
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting
  • Ellipses Pharma Limited Commercial
    ELACESTRANT; VOSILASARM
    2023-507738-26-00 1 country 2024 n=25
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502465-18-00 5 countries 2024 n=34
    Ended

Phase IV

2 trials
  • Institut fuer Frauengesundheit GmbH Academic
    IMP not specified
    2022-500764-35-00 1 country 2022 n=2,000
    Recruiting
  • Institut fuer Frauengesundheit GmbH Academic
    RIBOCICLIB
    2024-520290-12-00 1 country 2025 n=548
    Recruiting

Phase I

6 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523553-34-00 2 countries 2026 n=15
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended
  • Stemline Therapeutics Inc. Commercial
    IMP not specified
    2024-514661-19-01 1 country 2026 n=46
    Recruiting

Phase I (Other)

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506227-29-00 2 countries 2024 n=60
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2025-521924-31-00 1 country 2025 n=12
    Ended

Phase I (First in Human)

2 trials
  • Novartis Pharma AG Commercial
    ECI830
    2024-517281-42-00 6 countries 2025 n=59
    Recruiting
  • Novartis Pharma AG Commercial
    GVV858
    2025-521911-38-00 6 countries 2026 n=55
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 4 Phase III, Phase I (First in Human), Phase I/II 2
BeOne Medicines AG Commercial 3 Phase I 3
Merck Sharp & Dohme LLC Commercial 3 Phase II, Phase III 2
Stemline Therapeutics Inc. Commercial 2 Phase I, Phase III 2
Pfizer Inc. Commercial 2 Phase I (Other), Phase III 1
WSG Westdeutsche Studiengruppe GmbH Commercial 2 Phase III 1
BOOG Study Center B.V. Academic 2 Phase II, Phase III 0
Institut fuer Frauengesundheit GmbH Academic 2 Phase IV 2
Beigene Ltd. Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (Other) 1
Bicycletx Limited Commercial 1 Phase II 0
Medica Scientia Innovation Research S.L. Commercial 1 Phase II 0
Celcuity Inc. Commercial 1 Phase III 0
Dualitybio Inc. Commercial 1 Phase III 0
Genentech Inc. Commercial 1 Phase III 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase III 0
Relay Therapeutics Inc. Commercial 1 Phase III 1
Daiichi Sankyo Inc. Commercial 1 Phase I/II 1
Ellipses Pharma Limited Commercial 1 Phase I/II 1
New trials by year
2019
1
2021
2
2022
3
2023
2
2024
7
2025
13
2026
5
← All indication landscapes